Form 4: RELMADA CEO Boosts Stake with $113K Stock Purchase

RELMADA THERAPEUTICS CEO Sergio Traversa acquired 27,500 shares of common stock and was granted 1.2 million Stock Appreciation Rights.

Summary

• Sergio Traversa, CEO and Director of RELMADA THERAPEUTICS, INC. (RLMD), purchased 27,500 shares of common stock on December 15, 2025.
• The shares were acquired at a weighted average price of $4.12 per share, with prices ranging from $4.10 to $4.12, totaling approximately $113,300.
• Following this transaction, Mr. Traversa directly beneficially owns 1,300,000 shares of common stock.
• Additionally, on December 12, 2025, Mr. Traversa was granted 1,198,000 Stock Appreciation Rights (SARs) with an exercise price of $4.06.
• These SARs will vest in 16 equal quarterly installments, commencing on March 12, 2026, and have an expiration date of December 12, 2035.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by the CEO, indicating strong confidence in the company's future performance and valuation. The grant of long-term performance-based incentives further reinforces this positive outlook.

Positives

• The CEO's direct purchase of 27,500 shares of common stock signals strong confidence in the company's future prospects and valuation.
• The grant of 1,198,000 Stock Appreciation Rights (SARs) aligns management's long-term incentives directly with shareholder value creation, as SARs only gain value if the stock price increases above the exercise price.

Future Outlook

The vesting schedule for the Stock Appreciation Rights, commencing in March 2026 and extending over four years, indicates a long-term incentive structure for the CEO, aligning his financial interests with sustained future performance and shareholder value growth.

Industry Context

NA

Stakeholder Impact

• Shareholders: The CEO's increased ownership and long-term incentives suggest a stronger alignment of management's interests with shareholder value creation, potentially boosting investor confidence.

Next Steps

• Monitoring the vesting of the 1,198,000 Stock Appreciation Rights, which will occur in 16 equal quarterly installments starting March 12, 2026.

Key Dates

Recommendation

The CEO's significant open market purchase of company stock, coupled with a substantial grant of long-term performance-based Stock Appreciation Rights, provides a strong signal of management's conviction in the company's future prospects and potential for stock price appreciation. This insider confidence, particularly from the Chief Executive Officer, often precedes positive operational developments and is a compelling indicator for investors to consider a 'strong buy' position.

Keywords

RELMADA THERAPEUTICS, RLMD, Sergio Traversa, CEO, Insider Purchase, Stock Appreciation Rights, SARs, Common Stock, Beneficial Ownership, SEC Form 4